Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
A Phase I Pilot Study of SBRT and Concurrent Docetaxel for Reirradiation of Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
Sponsor: University of Cincinnati
Terminated
slow accrual
Other terminated trials from University of Cincinnati
Other Head and Neck Cancer trials with similar outcome
This PHASE1 trial investigates Head and Neck Cancer and is currently terminated or withdrawn. University of Cincinnati leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jun 2018 — Dec 2019 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Cincinnati
For direct contact, visit the study record on ClinicalTrials.gov .